Myasthenia Gravis Pipeline Insight
DelveInsight’s, “Myasthenia Gravis - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Myasthenia Gravis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Myasthenia Gravis Understanding
Myasthenia Gravis: Overview
Myasthenia Gravis (MG) is a neuromuscular disorder that causes weakness in the skeletal muscles, which are the muscles your body uses for movement. It occurs when communication between nerve cells and muscles becomes impaired. This impairment prevents crucial muscle contractions from occurring, resulting in muscle weakness. According to the Myasthenia Gravis Foundation of America, MG is the most common primary disorder of neuromuscular transmission. It’s a relatively rare condition that affects between 14 and 20 out of every 100,000 people in the United States.
The main symptom of MG is weakness in the voluntary skeletal muscles, which are muscles under your control. The failure of muscles to contract normally occurs because they can’t respond to nerve impulses. Without proper transmission of the impulse, the communication between nerve and muscle is blocked and weakness results. MG is a neuromuscular disorder that’s usually caused by an autoimmune problem. Autoimmune disorders occur when your immune system mistakenly attacks healthy tissue.
There is no cure for MG. The goal of treatment is to manage symptoms and control the activity of your immune system. Corticosteroids and immunosuppressants can be used to suppress the immune system. These medications help minimize the abnormal immune response that occurs in MG. Additionally, cholinesterase inhibitors, such as pyridostigmine (Mestinon), can be used to increase communication between nerves and muscles.
The companies and academics are working to assess challenges and seek opportunities that could influence Myasthenia gravis R&D. The therapies under development are focused on novel approaches for Myasthenia gravis.
Myasthenia Gravis Emerging Drugs Chapters
This segment of the Myasthenia Gravis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myasthenia Gravis Emerging Drugs
Efgartigimod is an investigational antibody fragment designed to reduce disease-causing immunoglobulin G (IgG) antibodies and block the IgG recycling process. Efgartigimod binds to the neonatal Fc receptor (FcRn), which is widely expressed throughout the body and plays a central role in rescuing IgG antibodies from degradation. Blocking FcRn reduces IgG antibody levels representing a logical potential therapeutic approach for several autoimmune diseases known to be driven by disease-causing IgG antibodies, including: myasthenia Gravis (MG), a chronic disease that causes muscle weakness.
In March 2021, Argenx announced FDA Acceptance of BLA Filing for Efgartigimod for the treatment of Generalized Myasthenia Gravis.
Argenx is also on track to submit an application for efgartigimod to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) in the first half of 2021 and the European Medicines Agency (EMA) in the second half of 2021.
Inebilizumab: Viela Bio
A humanized, affinity-optimized, afucosylated IgG1 kappa (IgG1κ) monoclonal antibody (mAb) that binds to the B cell-specific surface antigen CD19. It is currently in phase III and is being developed by Viela Bio.
Further product details are provided in the report……..
Myasthenia Gravis: Therapeutic Assessment
This segment of the report provides insights about the different Myasthenia Gravis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Myasthenia Gravis
There are approx. 10+ key companies which are developing the Myasthenia gravis. The companies which have their Myasthenia Gravis drug candidates in the most advanced stage, i.e. Preregistration include, Argenx.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Myasthenia Gravis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Myasthenia Gravis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Myasthenia Gravis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myasthenia Gravis drugs.
Myasthenia Gravis Report Insight
- Myasthenia Gravis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Myasthenia Gravis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Myasthenia Gravis drugs?
- How many Myasthenia Gravis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Myasthenia Gravis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Myasthenia Gravis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Myasthenia Gravis and their status?
- What are the key designations that have been granted to the emerging drugs?